Trial
NCT02305563
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Leukemia
Intervention
BMS-936564
Why stopped
Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-16